Global Blood-Brain Barrier Market Is Expected To Reach US$ 5,704.2 Mn During The Forecast Period 2018 - 2026

According to the latest report published by Brisk Insights “Blood-Brain Barrier Market - Growth, Future Prospects and Competitive Analysis, 2018-2026,” the blood brain barrier market was valued at USD 496.4 Mn in 2016, and is expected to reach USD 5,704.2 Mn by 2026, expanding at a CAGR of 25.0% from 2018 to 2026.

Browse the full report Blood-Brain Barrier Market - Growth, Future Prospects and Competitive Analysis, 2018-2026 report at  https://www.briskinsights.com/report/blood-brain-barrier-market

Market Insights

The blood-brain barrier (BBB) plays important role in protecting the brain from toxic compounds and blood-borne disorders. Thus, in case of central nervous system diseases it is vital to get treatments across this barrier and deliver desired effect at targeted location. According to experts, more than 98% of small molecules drugs and nearly 100% of larger biologic drugs cannot enter the brain at adequate concentrations to project therapeutic effects. The three main BBB permeation mechanisms that occur are passive diffusion, endocytosis, and active transport. Passive diffusion occurs by two mechanisms free and facilitated, endocytosis occurs by bulk phase and facilitated, and active transport through influx and efflux.  Technological development has introduced several key approaches for brain targeting include transport mechanisms such as cell-mediated endocytosis, reticence of active efflux pumps, adsorptive-mediated transcytosis, receptor-mediated transport, and the use of peptide vectors. Drug delivery technologies comprise delivery with assistance of liposomes, nanoparticles, nanogels, dendrimers, nanoemulsions, micelles, exosomes, polymersomes, and quantum dots.

According to market experts, increasing prevalence of neurological diseases, growing geriatric population, rising healthcare expenditure, mounting investment in pharmaceutical research and development, high awareness associated with chronic neurological diseases, and supportive policies and awareness campaigns organized by government organizations are observed as the key driving factors for significant growth of blood-brain barrier market.

By technology blood-brain barrier market is segmented as bispecific antibody RMT approach, Trojan Horse approach, increasing the permeability of BBB, passive diffusion, and other non-invasive BBB technologies. In year 2016, Trojan Horse approach was observed as largest segment in BBB market due to key factors such as the ability to deliver bispecific antibodies to the brain at therapeutic doses and its high membrane permeability. However, bispecific antibody RMT approach is expected to be the fastest growing segment due to entry of novel BBB technologies such as Ossianix Blood-Brain Barrier Technology (Ossianix) and Brain Shuttle Technology (Roche). Rising application of these two technologies in brain tumor treatment is expected to boost the overall growth of the segment throughout the forecast period 2018 - 2026.

On the basis of diseases, blood-brain barrier market was segmented as Alzheimer’s disease, Epilepsy, Parkinson’s disease, multiple sclerosis, Hunter’s syndrome, and Brain Cancer. In 2016, the BBB market was dominated by Alzheimer’s and Parkinson’s disease with more than 50% of the market share collectively owing to peaking prevalence of these diseases, introduction of technologically upgraded diagnostic technology for neurological diseases, and increasing awareness programs organized by non-governmental and governmental organizations. According to World Health Organization (WHO), around 50 million people globally have epilepsy, which makes it one of the most common neurological diseases globally and approximately 80% of the people with epilepsy live in low- and middle-income countries. Thus, incessant technological developments in the field of BBB is expected to assist the market growth throughout the forecast period 2018 – 2026.

Market Competition Assessment:

The blood brain barrier market is the most competitive market comprising large number of players with wide range of products and ongoing research and developments studies. The key players in this market are F. Hoffmann La-Roche, Ltd., Ossianix, Inc., Eli Lilly And Company, Bristol-Myers Squibb Company, Sanofi Genzyme, biOasia Technologies, Inc., Envivo Pharmaceuticals, Inc., Sagetis Biotech, Janssen Pharmaceutica NV, and ArmaGen among others.

Key Market Movements:

• Rising prevalence of neurological diseases coupled with rise in treatment limitations associated with blood-brain barrier
• Incessant growth in research and development  activities carried out in BBB technologies market